Eloxx Pharmaceuticals, Inc.
ELOX- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001035354
No open-market purchases or sales by Eloxx Pharmaceuticals, Inc. insiders were filed in the last 90 days; 22 institutions reported holding it in 13F filings for Q2 2026, worth $34.7M in total; no superinvestor holds it.
Q2 2022 vs. Q1 2022
How the institutions holding Eloxx Pharmaceuticals, Inc. changed between Q1 2022 and Q2 2022.
All holders in Q2 2022All holders in Q1 2022
| Measure | Q1 2022 | Q2 2022 | Change |
|---|---|---|---|
| Holders | 36 | 32 | −4 |
| Shares | 15.0M | 13.0M | −2.04M (−13.6%) |
| Value | $8.42M | $3.51M | −$4.91M (−58.4%) |
New holders (3)
Institutions that held Eloxx Pharmaceuticals, Inc. at the end of Q2 2022 but not at the end of Q1 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Renaissance Technologies LLC | 179,400 | $48.0K | 0.00% |
| Citadel Advisors LLC | 111,760 | $30.0K | 0.00% |
| Credit Suisse AG | 5 | $0 | 0.00% |
Sold out (7)
Institutions that held Eloxx Pharmaceuticals, Inc. at the end of Q1 2022 and filed for Q2 2022 without it.
| Institution | Shares, Q1 2022 | Value, Q1 2022 |
|---|---|---|
| Nantahala Capital Management, LLC | 774,767 | $434.0K |
| Millennium Management LLC | 105,883 | $59.0K |
| Two Sigma Investments, LP | 23,079 | $13.0K |
| UBS Group AG | 21,849 | $12.0K |
| Virtu Financial LLC | 20,504 | $11.0K |
| Jane Street Group, LLC | 20,354 | $11.0K |
| Susquehanna International Group, LLP | 11,860 | $7.00K |